On Jun. 2, 2021, Vaxxas announced that research demonstrated the potential of Vaxxasﾒ novel high-density microarray patch (HD-MAP) for vaccination against COVID-19 had been published in a manuscript posted to the preprint server BioRxiv.

Using a novel SARS-CoV-2 spike subunit vaccine, this preclinical study of Vaxxasﾒ HD-MAP showed enhancement of immune response compared to vaccination by needle-and-syringe, including significantly enhanced T-cell and spike-specific antibody responses as compared to needle-and-syringe delivery.